IVF Cycle Cost in Rhode Island

IVF Cycle in Rhode Island costs $13,560 to $28,250 in 2026, with a state-wide median of $20,340. Pricing varies by metro - typically $20,340 in Providence and $20,340 in Providence. Rhode Island pricing is 13% above the national average.

Providence typically has the lowest ivf cycle pricing in Rhode Island, with a median of $20,340 (1.13x national average). Mid-size markets generally run lower than major coastal or wealthy suburban areas.

Providence typically has the highest ivf cycle pricing in Rhode Island, with a median of $20,340 (1.13x national average). Larger metro areas with higher cost of living and more specialty providers tend to command premium pricing.

Insurance coverage for IVF varies dramatically by state. 21 states have some mandate as of 2026. Even with coverage, medications, PGT-A, and additional cycles are often partially uncovered. Most employer plans without state mandate offer no IVF benefit; some larger employers (Google, Meta, Bank of America, Starbucks) offer generous IVF benefits as a recruiting tool.

Rhode Island pricing is 13% above the national average. The state cost index is 1.13x the national average. Higher-cost states include California, New York, Massachusetts, and Washington DC; lower-cost states include Oklahoma, Mississippi, Kentucky, and Indiana.

Total out-of-pocket for one IVF cycle including medications typically runs $18,000 to $30,000 in the United States in 2026. Multi-cycle packages with money-back guarantees run $25,000-$50,000 for 2-3 cycles. Specific cost components: cycle fee ($12,000-$18,000), medications ($4,000-$7,000), ICSI if needed ($1,500-$3,000), PGT-A genetic testing ($3,500-$7,000), frozen embryo transfer ($3,500-$6,500).

21 states have some IVF insurance mandate as of 2026 (including Massachusetts, New York, New Jersey, Connecticut, Illinois, Maryland, Texas - partial). Even with coverage, medications, PGT-A genetic testing, and additional cycles often remain partially or fully out-of-pocket. Most employer-sponsored plans without mandate offer no IVF benefit.

Cumulative live birth rates reach approximately 65 percent after 3 cycles for women under 35. For women 35-37: 50 percent at 3 cycles. For women 38-40: 30 percent at 3 cycles. For women 42+: under 10 percent regardless of cycle count. Most successful patients complete 1-3 cycles.

Per-cycle live birth rates vary significantly by age (most important factor): 50+ percent for women under 35, 40 percent at 35-37, 26 percent at 38-40, 13 percent at 41-42, under 10 percent at 42+. SART (Society for Assisted Reproductive Technology) publishes clinic-specific outcomes at sart.org for direct comparison.

IVF is considered safe with extensive published outcome data. Risks include ovarian hyperstimulation syndrome (under 1 percent severe with modern protocols), multiple pregnancies (reduced with single-embryo transfer policy), procedural risks of egg retrieval (under 1 percent: bleeding, infection, anesthesia), and emotional/psychological stress of the process.